nvno stock — enVVeno Medical (NVNO) Overview

A comprehensive, beginner-friendly guide to nvno stock (enVVeno Medical Corporation): company profile, trading facts, product and regulatory status, financials, risks, and where to verify official ...

2024-07-12 00:24:00

By Blockchain Nomad

Article rating

4.8

113 ratings

Bitget offers a variety of ways to buy or sell popular cryptocurrencies. Buy now!

A welcome pack worth 6200 USDT for new users! Sign up now!

NVNO (enVVeno Medical Corporation) — Stock overview

nvno stock refers to the public equity ticker for enVVeno Medical Corporation, a U.S.-listed micro-cap medical device company focused on therapies for chronic venous insufficiency and related peripheral venous disease. This guide summarizes the company profile, trading venues, product and clinical development status, corporate events that have affected nvno stock, typical financial and liquidity characteristics for the name, principal risks, and where investors and researchers can verify facts via primary sources. Readers will learn how nvno stock typically trades, what regulatory milestones matter for valuation, and practical trading considerations (including using Bitget for execution and Bitget Wallet for custody). Please verify up-to-date quotes and filings before making any decisions.

Note: This article aims to be factual and neutral. It is not investment advice. For the latest market data on nvno stock consult live exchange quotes and the company’s SEC filings.

Company overview

enVVeno Medical Corporation is a development-stage medical device company focused on therapies for chronic venous insufficiency (CVI) and other peripheral venous disorders. The company’s core product candidates include implantable venous devices designed to restore or improve venous valve function and reduce symptoms associated with venous reflux and venous hypertension.

Historically, the company has described itself as focused on minimally invasive, implantable solutions intended to address a large addressable market of patients suffering from venous valve dysfunction. As a small, development-stage medical device firm, enVVeno typically operates without significant commercial revenue until product approvals and market launches occur.

As of the latest publicly available corporate disclosures, enVVeno’s operations center on progressing clinical development and regulatory submissions for leading device candidates such as the VenoValve and platform technologies named in company materials (for example, product references such as “VenoValve” and “enVVe” are used in company communications). For the most current company profile and official statements about headquarters, founding date, and leadership, consult the company’s SEC filings and investor relations materials.

Stock identification and exchanges

Ticker: NVNO (referred to throughout this article as nvno stock).
Primary listing: trades on a U.S. national exchange under the ticker NVNO; readers should verify the exact exchange (NASDAQ Capital Market or other venue) via an exchange quote page or the company’s filings.
Market classification: typically categorized as a micro-cap company (micro-cap classification applies when market capitalization is relatively small compared with mid- or large-cap peers).
CUSIP / ISIN: CUSIP and ISIN identifiers are available in SEC filings and on exchange quote pages; check the company’s latest Form 10-Q/10-K or the exchange listing page for the precise code.

As with all micro-cap tickers, the venue (primary exchange vs. OTC) and listing tier can change over time; consult the exchange listing notices and SEC filings for formal confirmation of listing status and any listing-related actions.

Trading and market data

nvno stock typically behaves like a development-stage micro-cap equity: trading occurs during regular US equity market hours, and some brokerages may offer pre-market and after-hours quotes where available. Liquidity and market activity for nvno stock are often lower than for larger, more widely followed companies, which can result in wider bid–ask spreads and larger price movements on relatively small volumes.

Typical trading characteristics for nvno stock (generalized for micro-cap medtech names):

Trading sessions: regular market hours (pre-market and after-hours may show quotes on many brokerages).
Liquidity: frequently limited; average daily volume (ADV) can be low relative to larger equities. For precise ADV, float, and shares outstanding, consult the exchange quote page and company filings.
Float and shares outstanding: float and fully diluted share counts are disclosed in periodic filings (Form 10-Q/10-K and registration statements). Dilution events (equity offerings, warrant exercises, convertible issuances) can materially change share counts.
Price ranges: micro-cap stocks can show wide intraday volatility and meaningful percentage swings relative to larger-cap names. The stock’s 52-week high/low and historical intraday ranges are available on exchange pages and major financial data portals.

As of 2026-01-20, according to company filings and exchange quote pages, nvno stock is characterized by low-to-moderate trading volume and a micro-cap market capitalization classification. For exact numeric measures — current share price, market capitalization, average daily volume, float, and 52-week range — consult live exchange quotes and recent SEC filings.

Historical market capitalization and classification

Micro-cap classification is defined differently by various vendors, but a common definition places micro-cap companies below $300 million in market capitalization and often below $50–100 million for the smallest names. nvno stock has typically been within the micro-cap range; changes in market cap reflect both market price movement and dilution from capital raises.

Important drivers of market-cap changes for nvno stock include:

Public offerings and registered direct offerings that increase outstanding shares.
Convertible debt issuances and warrant exercises that expand the potential share base.
Price volatility in response to clinical or regulatory news, which can rapidly change market capitalization even without share issuance.

Historical market-cap charts and the company’s disclosure of issued and outstanding shares are available in periodic filings and are the definitive source for measuring market-cap evolution over time.

Corporate history and timeline (Ticker-focused)

Below is a structured timeline template adapted for nvno stock that highlights categories of events investors typically track. For each listed event, readers should confirm dates and specifics in the company’s SEC filings and press releases.

Formation and early history: the company’s formation date, early management appointments, and initial financing rounds are summarized in the corporate filings (e.g., initial S-1 or registration statements where applicable).
Public listing: the listing date under the ticker NVNO on a U.S. national exchange (or OTC quoting date) is documented in the company’s registration statements and exchange announcements.
Clinical milestones: initiation of first-in-human studies, enrollment milestones (e.g., first patient treated), interim data readouts, and pivotal trial starts.
Regulatory submissions: filing of a PMA, investigational device exemption (IDE) communications with FDA, or pre-submission meetings (Pre-Sub) are typically described in press releases and 8-K disclosures.
Financing events: public offerings, registered direct offerings, PIPEs (private investments in public equity), convertible note issuances, or at-the-market (ATM) programs.
Corporate actions: reverse/forward splits, ticker changes, spin-offs, or delisting/listing notices.
Investor relations milestones: major investor presentations, SEC comment letter responses, or shareholder meeting outcomes.

As of 2026-01-20, company-reported milestones and public offerings affecting nvno stock include multiple financing events and clinical/regulatory communications; check the company’s Form 8-K and press release archive for dated entries and the SEC EDGAR database for official filing copies.

Notable corporate events (examples)

Regulatory submissions: reported PMA submission for a lead device candidate (for example, the VenoValve) and subsequent FDA interactions are material milestones for nvno stock.
Clinical releases: interim clinical data presentations at scientific meetings or published interim results often lead to material stock movements.
Financing announcements: registered offerings or PIPE closings that dilute existing holders typically appear in 8-K filings and affect nvno stock supply.
Corporate communications: management change announcements, strategic partnerships, or license agreements appear in 8-Ks and press releases and are commonly referenced when tracking nvno stock.

Always cross-check the exact dates and text of these events in the company’s SEC filings and official press releases before relying on them for analysis.

Products, clinical development and regulatory status

Principal product candidates described in company materials for enVVeno typically include implantable venous valve devices (e.g., VenoValve) designed to restore valvular function in patients with chronic venous insufficiency and related disorders. Device intent and development pathways commonly include:

Intended use: reconstruction or replacement of venous valves to reduce reflux and venous hypertension, thereby treating symptomology and potential tissue changes.
Clinical program: early feasibility studies, pivotal trials, and continued follow-up cohorts to demonstrate safety and effectiveness versus baseline or comparator endpoints.
Regulatory strategy: for a novel implantable venous valve system, a PMA (premarket approval) pathway is typical in the United States, often following IDE clinical work. Interactions with the FDA (Pre-Sub meetings, IDE approvals, PMA submissions) are critical program milestones.

Typical milestones to monitor for nvno stock include:

IDE or early feasibility study approvals enabling clinical enrollment.
Interim safety and effectiveness data readouts (e.g., symptom scores, duplex ultrasound valve competence, re-intervention rates).
PMA submission and any ensuing FDA communications (approvals, approvable/not-approvable letters, or requests for additional data).
Post-market study commitments if/when regulatory approval occurs.

As of 2026-01-20, company materials report ongoing clinical activities and regulatory interactions for the lead device(s). For the most recent trial results, PMA status, and regulatory letters, consult the company’s press releases and FDA public docket entries.

Financials

enVVeno, as a development-stage medical device company, typically reports limited or no product revenue until regulatory approvals and commercial launches are achieved. Key financial characteristics for nvno stock historically include:

Revenue: often minimal or none while advancing clinical programs.
Profitability: negative net income and negative EPS are common due to R&D spending and SG&A expenses.
Cash and liquidity: the company’s cash position, restricted cash, and short-term investments are reported in the balance sheet in periodic filings; these figures inform estimated runway and funding needs.
Debt: any outstanding convertible debt, term loans, or lines of credit will appear under liabilities and in the notes to the financial statements.
Burn rate: R&D and operating cash burn typically represent the largest use of cash for development-stage medtech companies.

Quarterly and annual highlights: the company publishes Form 10-Qs and 10-Ks that outline recent operating results, cash balances, working capital, and management commentary on runway. As of 2026-01-20, investors should consult the most recent Form 10-Q for quantitative balances (cash, liabilities, revenue, net loss) to assess financial position.

Note: financial metrics for micro-cap firms can change materially after a financing event or a non-dilutive capital partnership.

Capital raising and dilution

Capital markets transactions are common for micro-cap development companies advancing medical devices. For nvno stock, typical capital-raising activities include:

Registered public offerings and shelf takedowns.
Registered direct offerings and PIPEs to institutional or accredited investors.
At-the-market (ATM) facilities that allow the company to issue shares into the market over time.
Convertible debt or warrant packages that create potential future dilution.

Dilution effects: each equity issuance increases the number of outstanding shares and can materially affect per-share metrics and market capitalization. When tracking nvno stock, review the company’s recent prospectuses, Section 4(a)(2) disclosures if used, and 8-Ks announcing closings for precise share issuance counts and pricing.

Management commentary in earnings releases or investor presentations often provides information about anticipated runway and planned financing needs. As of 2026-01-20, the company’s filings indicate prior capital raises; for current outstanding share counts and potential dilution, consult the latest Form 10-Q or Form 10-K and any recent registration statements.

Corporate governance and management

Key governance items to consider when researching nvno stock:

Executive team: the CEO, CFO, and chief medical/scientific officers are frequently named in the company’s proxy statements and Form 10-K. Their industry experience, prior track records, and equity incentives are disclosed in filings.
Board composition: board members and committee assignments are described in proxy statements (DEF 14A) and Form 10-Ks.
Insider ownership: management and board ownership levels and recent insider transactions (buys/sells) are reported on Forms 3/4/5 and in proxy filings.
Institutional holders: major institutional or strategic investors often appear on 13G/13D filings and on the company’s beneficial ownership table in proxy materials.

When assessing nvno stock, note whether insiders and institutions have material stakes and whether insider transactions show meaningful buy or sell activity. For precise names, ownership percentages, and transaction dates, check Forms 3/4/5 and 13D/13G filings.

Analyst coverage and ratings

Many micro-cap medical device tickers do not receive broad sell-side coverage. Where analyst coverage exists for nvno stock, it typically comes from a small set of boutique research providers or independent analysts. Typical features of coverage:

Limited consensus ratings: there may be few or no widely published analyst ratings.
Wide variation in target prices: where coverage exists, target prices and ratings can be highly divergent due to differing views on clinical outcomes and regulatory timing.
Sources of commentary: market commentary often appears on financial portals, small-cap research newsletters, and specialist medtech research outlets.

Investors should treat any single analyst report as one data point and validate assumptions against primary source filings and clinical data.

Market performance and investor sentiment

Micro-cap medtech names like nvno stock tend to display higher volatility and episodic trading volume spikes around clinical readouts, regulatory news, or financing announcements. Common behavioral attributes:

Volatility: large percentage moves on relatively low absolute dollar volumes.
Retail interest: smaller stocks can attract concentrated retail attention and active trading on social platforms; social sentiment indicators (e.g., message board volume) can contribute to short-term price swings.
Technical observations: traders often look at position versus moving averages, recent breakout levels, and volume spikes when assessing momentum for nvno stock.

Because sentiment-driven moves can be rapid and short-lived, investors and traders should combine sentiment analysis with primary data (SEC filings and clinical results) when forming views.

Risks and controversies

Principal risks relevant to nvno stock include:

Clinical and regulatory risk: the outcome of pivotal trials and regulatory review (e.g., FDA PMA decisions) is uncertain; negative clinical data or an unfavorable regulatory letter can materially depress valuation.
Financing and dilution risk: as a development-stage company, enVVeno may require additional capital, which can lead to dilution through equity offerings, warrants, or convertible instruments.
Liquidity and volatility risk: low liquidity and large bid–ask spreads increase execution risk and may magnify volatility for nvno stock.
Listing/delisting risk: failure to meet exchange listing standards (e.g., minimum price, market cap, or reporting requirements) could lead to listing actions; review exchange notices and 8-K filings for any warnings.
Concentration risk: high insider or single-investor concentration can cause outsized price moves when large holders transact.
Legal and regulatory disputes: any litigation, FDA enforcement action, or material legal claim is usually disclosed in periodic filings and can be material to nvno stock.

Investors should read the company’s risk factors in the latest Form 10-K and 10-Q for a comprehensive and company-specific list of risks.

Recent news and press releases

For material events affecting nvno stock, primary sources include company press releases and SEC 8-K filings. Examples of news items that typically move micro-cap medtech shares:

Earnings and financial updates: quarterly results and cash-burn updates.
Clinical data: interim or pivotal trial readouts, safety signals, or re-intervention rates.
Regulatory actions: PMA submissions, FDA correspondence, or approval/denial letters.
Financing and corporate transactions: public offerings, private placements, or partnership announcements.

As of 2026-01-20, according to company press releases and SEC filings, enVVeno has reported ongoing clinical development and completed multiple financing events that have influenced nvno stock trading. For the definitive text and dates, consult the company’s press release archive and the corresponding 8-K filings.

SEC filings and investor resources

Primary sources are essential for verifying facts about nvno stock. Key resources:

SEC EDGAR: the definitive source for Forms 10-Q, 10-K, 8-K, registration statements (S-1, S-3), and proxy statements. Search by company name or ticker (NVNO) in EDGAR for dated filings.
Company investor relations: press releases, investor presentations, and SEC filing links are usually available on the company’s IR page.
Exchange listing pages and quote services: exchange pages show real-time quote data, historical prices, and listing status.
FDA public docket: for device-related regulatory correspondence and summaries (e.g., PMA summaries or advisory committee materials), check the FDA’s device approval and PMA databases.

As of 2026-01-20, the most recent quarterly and annual filings should be reviewed for up-to-date financial statements, share counts, and management discussion. Always rely on the original filing copies on EDGAR for authoritative text.

How to trade and invest (practical notes)

Practical considerations for anyone trading nvno stock:

Brokerage access: most U.S. brokerages that support small-cap equities will allow trading in nvno stock. For traders outside the U.S., check whether local brokers offer access to the exchange on which NVNO trades.
Order types: because of potential low liquidity and wide spreads, limit orders are generally recommended over market orders to control execution price and avoid large slippage when trading nvno stock.
Position sizing and risk management: due to high volatility, limit exposure per trade and use stop-loss or risk-defined position sizing appropriate for speculative micro-cap names.
Execution venue: consider using reputable exchanges and execution services. For users of the Bitget platform, Bitget offers market access for eligible equities; check Bitget’s product pages and customer support for details about availability of NVNO trading and any venue-specific execution parameters.
Custody: for non-custodial wallet needs or tokenized assets (if and when applicable), Bitget Wallet is the recommended web3 wallet in Bitget materials.

Before placing trades in nvno stock, review the latest filings, press releases, and real-time quotes. Micro-cap trading carries elevated execution and market risk.

References

The most reliable primary sources for verifying details about nvno stock include:

SEC EDGAR filings (Forms 10-Q, 10-K, 8-K, registration statements). As of 2026-01-20, see the company’s filings on EDGAR for up-to-date disclosures.
Company press releases and investor relations announcements. As of 2026-01-20, consult the company press release archive for dated statements that have affected nvno stock.
Exchange quote pages for NVNO, which report live price, 52-week ranges, and basic market metrics.
FDA public documents relating to device regulatory submissions and correspondence.

Examples of date-stamped statements you may find in these sources: "As of 2026-01-20, according to the company's Form 10-Q filed on [filing date], cash and cash equivalents were reported as disclosed in the balance sheet." Always open the primary filing to read the full text and confirm numbers.

External links

For authoritative, primary-source verification about nvno stock, consult the following resources (open these sites directly in your browser):

Company official website and investor relations page (press releases and presentations)
SEC EDGAR search (company filings by ticker NVNO)
Exchange quote page for NVNO (real-time price, 52-week range, volume)
FDA device and PMA databases for regulatory correspondence and summaries